Editorial| Volume 88, ISSUE 4, SUPPLEMENT 1, 1, August 16, 2001


      Extensive investigation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as statins, has established not only the profound lipid-lowering effects of these agents, but it has also confirmed the role of lipid-lowering therapy, in general, in the prevention of acute coronary events. The early benefit of statins demonstrated in primary- and secondary-prevention trials suggested mechanisms of action beyond lipid lowering, and prompted further investigation into their effects on the pathophysiology of atherosclerotic disease. Growing evidence points to the ability of statins to alter the structure of plaques and reduce inflammatory activity, making plaques more stable and less vulnerable to rupture. Statins have also been shown to restore impaired endothelial function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect